Archive | Evercyte GmbH

Page 1 of 15
Evercyte partners with AIM Biotech for microfluidic immortalized cell lines
Evercyte partners with AIM Biotech for microfluidic immortalized cell lines Learn More >
55389Evercyte adds telomerized perinatal cells to immortalized range
Evercyte adds telomerized perinatal cells to immortalized range Learn More >
55138Evercyte P-EP/SVTERT344 telomerized amniotic epithelial cells from placenta
Evercyte P-EP/SVTERT344 telomerized amniotic epithelial cells from placenta Learn More >
Evercyte to highlight immortalized cell potential in OOAC technology at SelectBIO Europe 2024 Congress
Evercyte to highlight immortalized cell potential in OOAC technology at SelectBIO Europe 2024 Congress Learn More >
Evercyte teams with Phoenestra and TAmiRNA to offer EVs at scale
Evercyte teams with Phoenestra and TAmiRNA to offer EVs at scale Learn More >
Evercyte contributing to reduced animal testing at key events
Evercyte contributing to reduced animal testing at key events Learn More >
Evercyte contributing to inaugural MOVE Symposium
Evercyte contributing to inaugural MOVE Symposium Learn More >
Evercyte promoting telomerized cell advantages at Small New World symposium
Evercyte promoting telomerized cell advantages at Small New World symposium Learn More >
53496Evercyte immortalized cell lines compatible with OOAC organ on chip technology
Evercyte immortalized cell lines compatible with OOAC organ on chip technology Learn More >
53451Evercyte EVs from human bone marrow-derived MSC (EV-BM-MSC/TERT292)
Evercyte EVs from human bone marrow-derived MSC (EV-BM-MSC/TERT292) Learn More >
Evercyte to showcase latest EV cell factories and recombinant antigen recognition at ISEV 2023 Seattle
Evercyte to showcase latest EV cell factories and recombinant antigen recognition at ISEV 2023 Seattle Learn More >
Evercyte brings EV and senescent cell expertise to EU Horizon CHANGE project
Evercyte brings EV and senescent cell expertise to EU Horizon CHANGE project Learn More >
Page 1 of 15